Literature DB >> 20171038

HIV testing and counseling in the nation's outpatient substance abuse treatment system, 1995-2005.

Harold A Pollack1, Thomas D'Aunno.   

Abstract

This article examines the extent to which U.S. outpatient substance abuse treatment (OSAT) facilities provide HIV counseling and testing (C&T) to clients between 1995 and 2005. We also examine organizational and client characteristics associated with OSAT facilities' provision of HIV C&T. Data were collected from a nationally representative sample of outpatient treatment facilities in 1995 (n = 618), 2000 (n = 571), and 2005 (n = 566). Results show that in 1995, 26.8% of OSAT clients received HIV C & T; by 2005, this proportion had increased, but only to 28.8%. Further, results from random-effects interval regression analysis show that C&T is especially widespread in public and nonprofit facilities, in methadone facilities, and in units that serve injection drug users and commercial sex workers. HIV C&T was also more widespread in units that employed formal intake protocols. Despite widespread efforts to increase HIV C&T services in OSAT care, only a small and stable minority of clients receive these services. Adoption of formal intake procedures may provide one vehicle to increase provision of C&T services. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20171038     DOI: 10.1016/j.jsat.2009.12.004

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  45 in total

1.  Patient characteristics and availability of onsite non-rapid and rapid HIV testing in US substance use disorder treatment programs.

Authors:  Amanda J Abraham; Lauren A O'Brien; Hannah K Knudsen; Brian E Bride; G Rush Smith; Paul M Roman
Journal:  J Subst Abuse Treat       Date:  2012-04-25

2.  Provision of onsite HIV Services in Substance Use Disorder Treatment Programs: A Longitudinal Analysis.

Authors:  Lydia Aletraris; Paul M Roman
Journal:  J Subst Abuse Treat       Date:  2015-04-13

3.  Human immunodeficiency virus testing practices among buprenorphine-prescribing physicians.

Authors:  E Jennifer Edelman; An T Dinh; Brent A Moore; Richard S Schottenfeld; David A Fiellin; Lynn E Sullivan
Journal:  J Addict Med       Date:  2012-06       Impact factor: 3.702

4.  Missed opportunities for hepatitis C testing in opioid treatment programs.

Authors:  Jemima A Frimpong
Journal:  Am J Public Health       Date:  2013-04-18       Impact factor: 9.308

5.  Determinants of the availability of hepatitis C testing services in opioid treatment programs: results from a national study.

Authors:  Jemima A Frimpong; Thomas D'Aunno; Lan Jiang
Journal:  Am J Public Health       Date:  2014-04-17       Impact factor: 9.308

Review 6.  A Critical Review and Commentary on the Challenges in Engaging HIV-Infected Latinos in the Continuum of HIV Care.

Authors:  Julie H Levison; Julia K Levinson; Margarita Alegría
Journal:  AIDS Behav       Date:  2018-08

7.  HIV rapid testing in drug treatment: comparison across treatment modalities.

Authors:  Robert P Schwartz; Maxine L Stitzer; Daniel J Feaster; P Todd Korthuis; Anika A H Alvanzo; Theresa M Winhusen; Lillian Donnard; Ned Snead; Lisa R Metsch
Journal:  J Subst Abuse Treat       Date:  2012-09-27

8.  Adoption of evidence-based clinical innovations: the case of buprenorphine use by opioid treatment programs.

Authors:  Christina M Andrews; Thomas A D'Aunno; Harold A Pollack; Peter D Friedmann
Journal:  Med Care Res Rev       Date:  2013-09-18       Impact factor: 3.929

9.  Foreign-born status as a predictor of engagement in HIV care in a large US metropolitan health system.

Authors:  Julie H Levison; Susan Regan; Iman Khan; Kenneth A Freedberg
Journal:  AIDS Care       Date:  2016-07-28

10.  Changes in testing for human immunodeficiency virus, sexually transmitted infections, and hepatitis C virus in opioid treatment programs.

Authors:  Marcus A Bachhuber; Chinazo O Cunningham
Journal:  JAMA       Date:  2013-12-25       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.